The Scottish Intercollegiate Guidelines Network (SIGN) and the British Thoracic Society (BTS) are inviting contributions on the key questions that will form the basis of new national guidelines on the management of asthma. The closing date for receipt of submissions is Sunday, 14 January.
Draft key questions have been formulated. The organisations say they are now “interested in knowing if the draft key questions address the main areas of concern or uncertainty among healthcare professionals managing the care of people with asthma.”
Currently, the draft questions include which initial add-on therapy is most effective in asthma which is inadequately controlled on inhaled corticosteroids (ICS); and which is the most effective add-on therapy for patients inadequately controlled on ICS plus long-acting beta agonists (LABA).
Also included in the draft list of questions is the benefit of an add-on monoclonal antibody in patients who are not adequately controlled on high-dose ICS plus LABA or oral corticosteroids. Add-on monoclonal antibodies in this patient group would be assessed in terms of the effects on the use of oral steroids, unscheduled care, side-effects, symptom control, treatment adherence and lung function. Other topics currently included for discussion in the upcoming guidelines are the use of extracorporeal membrane oxygenation in life-threatening or near-fatal asthma; the effect of sublingual immunotherapy in mono- or poly-sensitised asthma patients; and the role of bronchial thermoplasty in patients who are not adequately controlled on high-dose ICS plus LABA or oral corticosteroids.
A submission form detailing all proposed questions is available here. Before submissions are included for consideration, authors must complete the declaration of interest that is included in the feedback form. No comments will be considered without the completed declaration of interest.